This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mathas, S. Articles by Mapara, M. Y. Search for Related Content PubMed PubMed Citation Articles by Mathas, S. Articles by Mapara, M. Y.

Anti-CD20- and B-cell Receptor-mediated Apoptosis: Evidence for Shared Intracellular Signaling Pathways¹

University Medical Center Charité, Humboldt University, Robert-Rössle-Klinik, Department of Hematology, Oncology, and Tumor Immunology [S. M., B. D., M. Y. M.], and Max-Delbrück-Center for Molecular Medicine [A. R., K. B., B. D.], D-13125 Berlin, Germany

Clinical administration of the anti-CD20 antibody IDEC-C2B8 can induce remission of low-grade B-cell lymphoma. Whereas it has been suggested that the main mechanisms of action are complement-mediated and antibody-dependent cell-mediated cytotoxicity, we demonstrate that monoclonal antibody IDEC-C2B8 is a strong inducer of apoptosis in CD20-positive B-cell lymphoma cell lines reflecting different stages of lymphomagenesis. Thus, CD20-dependent apoptosis was inducible in human surface IgM-positive Burkitt’s lymphoma cell lines as well as in more mature surface IgM-negative B-cell lymphoma cell lines carrying the t(14;18) translocation. Furthermore, in Burkitt’s lymphoma cell lines, we observed a striking correlation between anti-CD20- and B-cell receptor-mediated apoptosis with regard to sensitivity toward the apoptotic stimuli and the execution of the apoptotic pathway. Thus, induction of anti-CD20- or B-cell receptor-mediated apoptosis involved rapid up-regulation of the proapoptotic protein Bax. In addition, we show similar changes in the mRNA expression level of two early response genes, c-myc and Berg36, as well as activation of the mitogen-activated protein kinase family members p44 (extracellular signal-regulated kinase 1) and p42 (extracellular signal-regulated kinase 2) and activation of activator protein 1 (AP-1) DNA binding activity. These data support our hypothesis that both pathways are mediated in part by the same signal-transducing molecules. These results might help explain the resistance and regression of lymphomas to IDEC-C2B8 and give new insights in the signaling cascade after CD20 ligation.

This article has been cited by other articles:

				B. Li, L. Zhao, H. Guo, C. Wang, X. Zhang, L. Wu, L. Chen, Q. Tong, W. Qian, H. Wang, et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma Blood, December 3, 2009; 114(24): 5007 - 5015. [Abstract] [Full Text] [PDF]

				S. P. Hilchey, O. Hyrien, T. R. Mosmann, A. M. Livingstone, J. W. Friedberg, F. Young, R. I. Fisher, R. J. Kelleher Jr, R. B. Bankert, and S. H. Bernstein Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab Blood, April 16, 2009; 113(16): 3809 - 3812. [Abstract] [Full Text] [PDF]

				S. Dalle, S. Dupire, S. Brunet-Manquat, L. Reslan, A. Plesa, and C. Dumontet In vivo Model of Follicular Lymphoma Resistant to Rituximab Clin. Cancer Res., February 1, 2009; 15(3): 851 - 857. [Abstract] [Full Text] [PDF]

				A. Mankai, A. Bordron, Y. Renaudineau, C. Martins-Carvalho, S. Takahashi, I. Ghedira, C. Berthou, and P. Youinou Purine-Rich Box-1-Mediated Reduced Expression of CD20 Alters Rituximab-Induced Lysis of Chronic Lymphocytic Leukemia B Cells Cancer Res., September 15, 2008; 68(18): 7512 - 7519. [Abstract] [Full Text] [PDF]

				A. Ivanov, S. Krysov, M. S. Cragg, and T. Illidge Radiation Therapy with Tositumomab (B1) Anti-CD20 Monoclonal Antibody Initiates Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase-Dependent Cell Death that Overcomes Resistance to Apoptosis Clin. Cancer Res., August 1, 2008; 14(15): 4925 - 4934. [Abstract] [Full Text] [PDF]

				P. V. Beum, M. A. Lindorfer, F. Beurskens, P. T. Stukenberg, H. M. Lokhorst, A. W. Pawluczkowycz, P. W. H. I. Parren, J. G. J. van de Winkel, and R. P. Taylor Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis J. Immunol., July 1, 2008; 181(1): 822 - 832. [Abstract] [Full Text] [PDF]

				C. A. Walshe, S. A. Beers, R. R. French, C. H. T. Chan, P. W. Johnson, G. K. Packham, M. J. Glennie, and M. S. Cragg Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling J. Biol. Chem., June 20, 2008; 283(25): 16971 - 16984. [Abstract] [Full Text] [PDF]

				N. S. Kapadia, J. M. Engles, and R. L. Wahl In Vitro Evaluation of Radioprotective and Radiosensitizing Effects of Rituximab J. Nucl. Med., April 1, 2008; 49(4): 674 - 678. [Abstract] [Full Text] [PDF]

				M. S. Czuczman, S. Olejniczak, A. Gowda, A. Kotowski, A. Binder, H. Kaur, J. Knight, P. Starostik, J. Deans, and F. J. Hernandez-Ilizaliturri Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels Clin. Cancer Res., March 1, 2008; 14(5): 1561 - 1570. [Abstract] [Full Text] [PDF]

				A. J. Stel, B. ten Cate, S. Jacobs, J. W. Kok, D. C. J. Spierings, M. Dondorff, W. Helfrich, H. C. Kluin-Nelemans, L. F. M. H. de Leij, S. Withoff, et al. Fas Receptor Clustering and Involvement of the Death Receptor Pathway in Rituximab-Mediated Apoptosis with Concomitant Sensitization of Lymphoma B Cells to Fas-Induced Apoptosis J. Immunol., February 15, 2007; 178(4): 2287 - 2295. [Abstract] [Full Text] [PDF]

				S. M. Ansell, S. M. Geyer, M. J. Maurer, P. J. Kurtin, I. N.M. Micallef, P. Stella, P. Etzell, A. J. Novak, C. Erlichman, and T. E. Witzig Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients. Clin. Cancer Res., October 15, 2006; 12(20): 6056 - 6063. [Abstract] [Full Text] [PDF]

				D. Decaudin, P. de Cremoux, A. Vincent-Salomon, R. Dendale, and L. L.-L. Rouic Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options Blood, September 1, 2006; 108(5): 1451 - 1460. [Abstract] [Full Text] [PDF]

				S. Mathas, K. Johrens, S. Joos, A. Lietz, F. Hummel, M. Janz, F. Jundt, I. Anagnostopoulos, K. Bommert, P. Lichter, et al. Elevated NF-{kappa}B p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas Blood, December 15, 2005; 106(13): 4287 - 4293. [Abstract] [Full Text] [PDF]

				F. J. Hernandez-Ilizaliturri, N. Reddy, B. Holkova, E. Ottman, and M. S. Czuczman Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model Clin. Cancer Res., August 15, 2005; 11(16): 5984 - 5992. [Abstract] [Full Text] [PDF]

				W. Wojciechowski, H. Li, S. Marshall, C. Dell'Agnola, and I. Espinoza-Delgado Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms J. Immunol., June 15, 2005; 174(12): 7859 - 7868. [Abstract] [Full Text] [PDF]

				A. J. Stel, B.-J. Kroesen, S. Jacobs, H. Groen, L. F. M. H. de Leij, H. C. Kluin-Nelemans, and S. Withoff The Role of B Cell-Mediated T Cell Costimulation in the Efficacy of the T Cell Retargeting Bispecific Antibody BIS20x3 J. Immunol., November 15, 2004; 173(10): 6009 - 6016. [Abstract] [Full Text] [PDF]

				G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny From the bench to the bedside: ways to improve rituximab efficacy Blood, November 1, 2004; 104(9): 2635 - 2642. [Abstract] [Full Text] [PDF]

				A. R. Jazirehi, M. I. Vega, D. Chatterjee, L. Goodglick, and B. Bonavida Inhibition of the Raf-MEK1/2-ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin's Lymphoma B Cells by Rituximab Cancer Res., October 1, 2004; 64(19): 7117 - 7126. [Abstract] [Full Text] [PDF]

				C. Bezombes, S. Grazide, C. Garret, C. Fabre, A. Quillet-Mary, S. Muller, J.-P. Jaffrezou, and G. Laurent Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains Blood, August 15, 2004; 104(4): 1166 - 1173. [Abstract] [Full Text] [PDF]

				A. J. Olszewski and M. L. Grossbard Empowering Targeted Therapy: Lessons from Rituximab Sci. Signal., July 13, 2004; 2004(241): pe30 - pe30. [Abstract] [Full Text] [PDF]

				S. Dall'Ozzo, S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, H. Watier, and G. Thibault Rituximab-Dependent Cytotoxicity by Natural Killer Cells: Influence of FCGR3A Polymorphism on the Concentration-Effect Relationship Cancer Res., July 1, 2004; 64(13): 4664 - 4669. [Abstract] [Full Text] [PDF]

				J. Uchida, Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor-dependent Mechanisms during Anti-CD20 Antibody Immunotherapy J. Exp. Med., June 21, 2004; 199(12): 1659 - 1669. [Abstract] [Full Text] [PDF]

				W. L. Gluck, D. Hurst, A. Yuen, A. M. Levine, M. A. Dayton, J. P. Gockerman, J. Lucas, K. Denis-Mize, B. Tong, D. Navis, et al. Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin's Lymphoma: IL-2 Mediated Natural Killer Cell Expansion Correlations with Clinical Response Clin. Cancer Res., April 1, 2004; 10(7): 2253 - 2264. [Abstract] [Full Text] [PDF]

				M. S. Cragg and M. J. Glennie Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents Blood, April 1, 2004; 103(7): 2738 - 2743. [Abstract] [Full Text] [PDF]

				M. Y. Mapara and M. Sykes Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance J. Clin. Oncol., March 15, 2004; 22(6): 1136 - 1151. [Abstract] [Full Text] [PDF]

				A. Dupuy, M. Viguier, C. Bedane, F. Cordoliani, S. Blaise, F. Aucouturier, J.-M. Bonnetblanc, P. Morel, L. Dubertret, and H. Bachelez Treatment of Refractory Pemphigus Vulgaris With Rituximab (Anti-CD20 Monoclonal Antibody) Arch Dermatol, January 1, 2004; 140(1): 91 - 96. [Abstract] [Full Text] [PDF]

				F. J. Hernandez-Ilizaliturri, V. Jupudy, J. Ostberg, E. Oflazoglu, A. Huberman, E. Repasky, and M. S. Czuczman Neutrophils Contribute to the Biological Antitumor Activity of Rituximab in a Non-Hodgkin's Lymphoma Severe Combined Immunodeficiency Mouse Model Clin. Cancer Res., December 1, 2003; 9(16): 5866 - 5873. [Abstract] [Full Text] [PDF]

				H. T. C. Chan, D. Hughes, R. R. French, A. L. Tutt, C. A. Walshe, J. L. Teeling, M. J. Glennie, and M. S. Cragg CD20-induced Lymphoma Cell Death Is Independent of Both Caspases and Its Redistribution into Triton X-100 Insoluble Membrane Rafts Cancer Res., September 1, 2003; 63(17): 5480 - 5489. [Abstract] [Full Text] [PDF]

				O. Manches, G. Lui, L. Chaperot, R. Gressin, J.-P. Molens, M.-C. Jacob, J.-J. Sotto, D. Leroux, J.-C. Bensa, and J. Plumas In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas Blood, February 1, 2003; 101(3): 949 - 954. [Abstract] [Full Text] [PDF]

				D. Decaudin, G. Des Guetz, C. Mathiot, J. Dumont, P. Hubert, A. Vincent-Salomon, and P. Pouillart Absolute lymphocyte count as a predictive factor for response to monoclonal anti-CD20 antibody therapy Ann. Onc., January 1, 2003; 14(1): 171 - 172. [Full Text] [PDF]

				M. J. Polyak and J. P. Deans Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure Blood, May 1, 2002; 99(9): 3256 - 3262. [Abstract] [Full Text] [PDF]

				I. M. Pedersen, A. M. Buhl, P. Klausen, C. H. Geisler, and J. Jurlander The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism Blood, February 15, 2002; 99(4): 1314 - 1319. [Abstract] [Full Text] [PDF]

				S. M. Ansell, T. E. Witzig, P. J. Kurtin, J. A. Sloan, D. F. Jelinek, K. G. Howell, S. N. Markovic, T. M. Habermann, G. G. Klee, P. J. Atherton, et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma Blood, January 1, 2002; 99(1): 67 - 74. [Abstract] [Full Text] [PDF]

				J. Golay, M. Lazzari, V. Facchinetti, S. Bernasconi, G. Borleri, T. Barbui, A. Rambaldi, and M. Introna CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 Blood, December 1, 2001; 98(12): 3383 - 3389. [Abstract] [Full Text] [PDF]